What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1432839

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1432839

Asia Pacific Nuclear Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

PAGES: 90 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The Asia Pacific Nuclear Imaging Market size is estimated at USD 1.52 billion in 2024, and is expected to reach USD 1.88 billion by 2029, growing at a CAGR of 4.23% during the forecast period (2024-2029).

Asia Pacific Nuclear Imaging - Market

The factors that are propelling the growth of the market include technological advancements, increasing diagnostic applications in various diseases, such as cancer and cardiovascular diseases, and the growing burden of these chronic diseases.

Over recent years, scientists, researchers, and technologists have been able to bring systems in clinical practice, in which two or even more than two standalone diagnostic imaging modalities are combined. Some of those multimodality imaging systems include PET/CT, SPECT/CT, PET/MRI, and PET/SPECT/CT. The shift from standalone to hybrid modalities have improved the applications of these devices in recent times.

Moreover, the rise in the prevalence of cancer and cardiac ailments is one of the primary drivers for the market. Nuclear medicine is hugely capable of treating cancer and cardiac diseases. Asia Pacific region has the highest populous countries like China and India, which in turn contribute to a large aging population. There is also a higher disease incidence in this region increases the demand for advanced technologies like nuclear imaging. There is a large investment on the healthcare setup and medical research making these facilities accessible. The per capita income is increasing in these countries making such technologies more affordable.

APAC Nuclear Imaging Devices Market Trends

Cardiology is Expected to Hold the Highest Market Share in the Region

Cardiac nuclear medicine exams provide pictures of the distribution of blood flow to the heart muscle and can be used to visualize the function of the heart. This technique has applications in the diagnosis of various cardiovascular diseases such as angina, aneurysm, atherosclerosis, stroke, coronary artery disease, and congestive heart failure. It is also used to evaluate cardiomyopathy and identify possible damage to the heart from chemotherapy or radiotherapy.

As per a 2019 report by Prabha Desikan et al, published in Circulation: Cardiovascular Quality and Outcomes, CVDs are the leading cause of mortality in India. This epidemiological transition is large because of the increase in the prevalence of CVDs and CVD risk factors in India.

Gamma cameras and positron emission tomography scanners are the major imaging devices used in cardiac procedures. SPECT imaging has been the mainstream modality for nuclear cardiology procedures performed worldwide.

Therefore the increasing prevalence of cardiovascular diseases is found contributing to the growth of the market for nuclear imaging equipment.

APAC Nuclear Imaging Devices Industry Overview

The Asia Pacific nuclear imaging market is highly competitive and consists of a few major players. In terms of market share, few of the major players currently dominate the market. Companies, like Koninklijke Philips NV, GE Healthcare, and Siemens Healthineers, among others, hold a substantial share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 53698



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders
    • 4.2.2 Increase in Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Limited Reimbursement and Stringent Regulatory Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product Type
    • 5.1.1 Equipment
    • 5.1.2 Radioisotope
      • SPECT Radioisotopes
      • Technetium-99m (TC-99m)
      • Thallium-201 (TI-201)
      • Gallium(Ga-67)
      • Iodine (I-123)
      • Other SPECT Radioisotopes
      • PET Radioisotopes
      • Fluorine-18 (F-18)
      • Rubidium-82 (RB-82)
      • Other PET Radioisotopes
  • 5.2 By Application
    • 5.2.1 SPECT Applications
      • Cardiology
      • Neurology
      • Thyroid
      • Other SPECT Applications
    • 5.2.2 PET Applications
      • Oncology
      • Cardiology
      • Neurology
      • Other PET Applications
  • 5.3 Geography
    • 5.3.1


      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific


  • 6.1 Company Profiles
    • 6.1.1 Canon Medical Systems Corporation
    • 6.1.2 Siemens Healthineers
    • 6.1.3 Koninklijke Philips NV
    • 6.1.4 GE Healthcare
    • 6.1.5 Neusoft Medical Systems Co., Ltd.
    • 6.1.6 MiE GmbH
    • 6.1.7 Urenco
    • 6.1.8 Taiyo Nippon Sanso
    • 6.1.9 Bracco Imaging SpA


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!